Absence of prolactin gene expression in colorectal cancer

Journal of Clinical Pathology - Molecular Pathology

Volumn 52, Issue 3, 1999, Pages 135-139

  Wood, A J ^a   Thomas, C M ^a   Baumforth, K R N ^b   Flavell, J R ^b   Scott, K W M ^a   Grace, R H ^a   Williams, J G ^a   Holland, M R ^a   Dunn, R ^a   Jacobs, A G ^a   Harrison, A ^c   Brun, S ^d   Plessis, N ^d   Murray, P G ^b  

^a NEW CROSS HOSPITAL   (United Kingdom)

^b UNIVERSITY OF WOLVERHAMPTON   (United Kingdom)

^c JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^d UNIV MONTPELLIER   (France)

Author keywords

Colorectal cancer; Immunohistochemistry; Prolactin

Indexed keywords

PROLACTIN;

ARTICLE; CANCER GENETICS; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; GENE EXPRESSION REGULATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERPROLACTINEMIA; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTIN RELEASE;

EID: 0033000791     PISSN: 13668714     EISSN: None     Source Type: Journal    
DOI: 10.1136/mp.52.3.135     Document Type: Article

References (17)

1. 1 Bhatavdekar JM, Shah NG, Balar DB, et al. Plasma prolactin as an indicator of disease progression in advanced breast cancer. Cancer 1990;65:2028-32.
2. 2 Bhatavdekar JM, Giri DD, Shah NG, et al. Prolactin in advanced breast cancer. An Indian experience. Breast Diseases 1990;3:199-204.
3. 3 Bhatavdekar JM, Patel DD, Giri DD, et al. Comparison of plasma prolactin and CEA in monitoring patients with adenocarcinoma of the colon and rectum. Br J Cancer 1992;66:977-80.
4. 4 Patel DD, Bhatavdekar JM, Ghosh A, et al. Plasma prolactin in patients with colorectal cancer. Cancer 1994;73:570-4.
5. 5 Ilan Y, Sibirsky O, Livini A, et al. Plasma and tumour prolactin in colorectal cancer patients. Dig Dis Sci 1995;40: 2010-15.
6. 6 Benker G, Jaspers C, Hausler G, et al. Control of prolactin secretion. Klin Wochensehr 1990;68:1157-67.
7. 7 Marshall WJ. Clinical chemistry, 2nd ed. New York: Gower Medical Publishing, 1992.
8. 8 Crozier TA, Muller JE, Quittkat D, et al. Effect of anaesthesia on the cytokine responses to abdominal surgery. Br J Anaesth 1994;72:280-5.
9. 9 O'Leary E, Hubbard K, Tormey W, et al. Laparoscopic cholecystectomy: haemodynamic and neuroendocrine responses after pneumoperitoncum and changes in position. Br J Anaesth 1996;76:640-4.
10. 10 Reber A, Huber PR, Ummenhofer W, et al. General anaesthesia for surgery can influence circulating melatonin during daylight hours. Acta Anaesthesiol Scand 1998;42:1050-6.
11. 11 Gerli R, Rambotti P, Nicoletti I, et al. Reduced number of natural killer cells in patients with pathological hyperprolactinaemia. Clin Exp Immunol 1986;64:399-406.
12. 12 Vidaller A, Guadarrama F, Llorente L, et al. Hyperprol-actinemia inhibits natural killer (NK) cell function in vivo and its bromocriptine treatment not only corrects it but makes it more efficient. J Clin Immunol 1992;12:210-15.
13. 13 Matera L, Ciccarelli E, Cesano A, et al. Natural killer activity in hyperprolactinemic patients. Immunopharmacology 1989;18:143-6.
14. 14 Provinciali M, Di Stefano G, Stronati S, et al. Role of prolactin in the modulation of NK and LAK cell activity after short-or long-term morphine administration in neoplastic patients. Int J Immunopharmacol 1996;10:577-86.
15. 15 Oberholtzer E, Contarini M, Veglia F, et al. Prolactin increases the susceptibility of primary leukemia cells to NK and LAK effectors. Adv Neuroimmunol 1996;6:233-47.
16. 16 Chakraborty A, Chakraborty NG, Chattopadhyay U. Prolactin response of NK cells, but not of LAK cells, is deficient in patients with carcinoma of oral cavity and during aging. Int J Cancer 1996;66:65-9.
17. 17 Nagano M, Chastre E, Choquet A, et al. Expression of prolactin and growth hormone receptor genes and their isoforms in the gastrointestinal tract. Am J Physiol 1995;268:G431-42.